IPC
NBIX icon

Independent Portfolio Consultants’s Neurocrine Biosciences NBIX Stock Holding History

Independent Portfolio Consultants’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$102K Sell
2,210
-235
-10% -$11.4K 0.04% 409
2017
Q1 		$106K Buy
+2,445
New +$105K 0.04% 437

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Independent Portfolio Consultants's NBIX Position: Q2 2017 in Review

Independent Portfolio Consultants reduced its Neurocrine Biosciences (NBIX) stake by 9.6% in Q2 2017, selling an estimated $11.4K and leaving 2,210 shares worth $102K. The position accounts for 0.04% of the portfolio, ranked #409.

Independent Portfolio Consultants first reported a position in NBIX in Q1 2017 and has held it in 2 quarters since. The position peaked at $106K in Q1 2017. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

  • Independent Portfolio Consultants held 2,210 shares of Neurocrine Biosciences worth $102K as of Q2 2017.
  • Independent Portfolio Consultants sold 235 Neurocrine Biosciences shares in Q2 2017, an estimated $11.4K.
  • Neurocrine Biosciences made up 0.04% of Independent Portfolio Consultants's portfolio in Q2 2017, its #409 holding.
  • Independent Portfolio Consultants first reported a position in Neurocrine Biosciences in Q1 2017 and has held it in 2 quarters since.
  • Independent Portfolio Consultants's Neurocrine Biosciences position peaked at $106K in Q1 2017.
  • 221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.